Specific issues of using modern anticoagulants for prescribing thromboembolic complications during surgical interventions
Open Access
- 15 October 2026
- journal article
- Published by Yakutsk Scientific Center for Complex Medical Problems in Yakut Medical Journal
- No. 3,p. 45-50
Abstract
Thromboembolic complications are among the most dangerous and, unfortunately, the most common lethal complications of elective surgical interventions. Today, anticoagulant therapy plays a leading role in preventing their occurrence in everyday clinical practice. A significant increase in the number of comorbid patients with the need for anticoagulant therapy for the prevention or treatment of venous thromboembolic complications requires surgeons to be aware of the specific issues of prescribing and/or discontinuing modern anticoagulant drugs. Today, low-molecular-weight heparins are the drugs of choice for routine prevention and long-term treatment of thrombotic complications. Traditionally, medical professionals consider these drugs similar and interchangeable, but they differ significantly in terms of their relative antithrombin activity, indications and contraindications in specific clinical situations, and the principles of dose adjustment. Currently, most patients requiring elective surgical interventions require a personalized approach to anticoagulant therapy.Keywords
This publication has 36 references indexed in Scilit:
- Perioperative Factor Xa Inhibitor Discontinuation for Patients Undergoing Procedures With Minimal or Low Bleeding RiskJAMA Network Open, 2025
- Perioperative Management of Patients Taking Direct Oral AnticoagulantsJAMA, 2024
- Expanding Indications of Nonvitamin K Oral Anticoagulants Beyond Nonvalvular Atrial Fibrillation and Venous Thromboembolism: A Review of Emerging Clinical EvidenceCurrent Problems in Cardiology, 2023
- Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous ThrombosisEuropean Journal of Vascular and Endovascular Surgery, 2021
- Thromboembolic and bleeding risk of periprocedural bridging anticoagulation: A systematic review and meta‐analysisClinical Cardiology, 2020
- Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgeryCochrane Database of Systematic Reviews, 2019
- A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairmentJournal of Thrombosis and Thrombolysis, 2016
- Antithrombotic Therapy for VTE DiseaseChest, 2016
- Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancerCochrane Database of Systematic Reviews, 2014
- Preoperative or Postoperative Start of Prophylaxis for Venous Thromboembolism With Low-Molecular-Weight Heparin in Elective Hip Surgery?Archives of internal medicine (1960), 2002